logo
Goutham Sunkara's Insights on Automating Network Testing for Scalable SD-WAN Deployments

Goutham Sunkara's Insights on Automating Network Testing for Scalable SD-WAN Deployments

In today's fast-changing world of network technology, Software-Defined Wide Area Networking (SD-WAN) has become a key tool for companies looking for flexible, secure, and efficient connections. Goutham Sunkara, an experienced Staff R&D Software Engineer with over 10 years of expertise in network security and automation, has played a big role in making SD-WAN systems reliable and high-performing. His work at Cisco Systems and VMware by Broadcom Inc. shows how important automation is for testing SD-WAN features, providing useful lessons for network engineers and companies wanting to improve their networks.
At Cisco Systems, where Goutham Sunkara worked as a Software Engineer III from July 2018 to August 2021, he had a key role in testing SD-WAN features on Cisco's ISR 4K, 1K, and Catalyst 8K routers. He focused on making sure the network routing was secure and worked well, which is a big part of what makes SD-WAN valuable. Sunkara's testing was thorough, covering how the features worked, how they handled large-scale use, their performance, and checks to ensure nothing broke over time. He created detailed plans and used both manual and automated tests to make sure Cisco's SD-WAN systems were strong and secure. His work included checking SD-WAN security features and how they worked with ISR routers, fixing weaknesses in systems like IPsec, MPLS, and DMVPN. This careful testing was essential to keep data safe and ensure networks stayed reliable, especially for big businesses that need dependable systems.
A big part of Goutham Sunkara's work at Cisco was creating automation scripts using Python and the PyATS tool on Linux systems. These scripts made it easier and faster to test important network features like encryption, VPN security, and firewall rules. By automating these security tests, Sunkara saved time in finding and fixing problems, making sure Cisco's ISR routers were secure and worked well. His automation also tested a wide range of network protocols, like NAT, HTTP, IPv4/IPv6, and routing protocols such as OSPF and BGP. This complete approach not only sped up testing but also gave helpful information to the development and marketing teams, encouraging teamwork to improve product security from start to finish.
Goutham Sunkara brought his automation skills to his job at VMware by Broadcom Inc., where he has worked as a Staff R&D Software Engineer since August 2021. He focused on the NSX-T platform, a software-based networking tool that works well with SD-WAN to create secure and flexible networks. Sunkara led the testing strategy and automation for NSX-T's Security Service Platform (SSP), a security product powered by AI and machine learning. He created automation scripts using Python and REST APIs to test new NSX-T features, like Distributed Firewall (DFW) on Distributed Virtual Port Groups (DVPGs), Fully Qualified Domain Name (FQDN) filtering, and NSX Edge Cluster setups. These scripts made it faster to check complex features, ensuring they worked reliably in different network situations.
One of Goutham Sunkara's key accomplishments at VMware was building test framework libraries to support new NSX-T features, like Network Detection and Response (NDR) sensors, application discovery, and monitoring tools. He automated tests for East-West traffic between Linux and Windows virtual machines using tools like Spirent, CyPerf, and Cyberflood, ensuring thorough testing of Intrusion Detection and Prevention Systems (IDPS) and Malware Prevention Systems (MPS). This automation was essential for checking the security and performance of distributed firewalls in software-defined data centers (SDDCs). Sunkara's careful approach to creating and running test plans, including setting up ESXi hosts, configuring DHCP/DNS/vCenter, and deploying Spirent VMs, made sure the SDDC test environments were strong and mirrored real-world setups.
Goutham Sunkara's education strengthened his skills in network automation. While earning his Master's in Electrical Engineering at San Jose State University, he researched adaptive bit rate streaming and ways to stop Denial-of-Service (DoS) attacks, using tools like GNS3, Wireshark, and NS-3. These projects helped him learn how to design and test complex networks, skills he later used for SD-WAN and software-defined data center (SDDC) testing. His certifications, such as Cisco Certified Network Associate (CCNA) and VMware's VCP-DCV and VCP-NV, show his strong knowledge in routing, switching, and network virtualization.
Goutham Sunkara's work gives network engineers helpful tips for automating SD-WAN testing. He stresses the need to include security testing in automation, making sure protocols like IPsec and firewall rules are thoroughly checked. His use of Python-based automation tools shows how scripts can save time and make tests more accurate. Sunkara's experience also shows the importance of teamwork, as he worked with development and feature teams to ensure testing matches product goals.
As companies increasingly use SD-WAN to support remote workers and cloud apps, Goutham Sunkara's work shows how automation helps create flexible, secure, and reliable networks. His expertise in building and running automated test strategies at Cisco and VMware offers a clear guide for businesses looking to improve their SD-WAN setups, ensuring strong performance and security in today's complex digital world.
TIME BUSINESS NEWS
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morgan Stanley Sees Balanced Outlook for Verizon (VZ)
Morgan Stanley Sees Balanced Outlook for Verizon (VZ)

Yahoo

time34 minutes ago

  • Yahoo

Morgan Stanley Sees Balanced Outlook for Verizon (VZ)

Verizon Communications Inc. (NYSE:VZ) ranks among the . With a $47 price target and an Equalweight rating, Morgan Stanley resumed covering Verizon Communications Inc. (NYSE:VZ) on July 10. As the company is trading at a minor discount to its peer group, the firm believes that VZ shares have a balanced risk-reward profile at current prices. This is in line with Morgan Stanley's projected adjusted EBITDA growth rate of 2-3%. Ken Wolter / The firm presented a bull case price target of $54, which would represent the advantages of faster expansion in the broadband and consumer wireless segments. In this scenario, adjusted EBITDA growth could reach 3-3.5% annually, potentially enabling Verizon Communications Inc. (NYSE:VZ) shares to close the valuation gap with AT&T. Verizon Communications Inc. (NYSE:VZ) is a leading provider of technology, entertainment, and communication services worldwide. The company offers a range of services through its operational divisions, such as digital TV, high-speed internet, and 5G and 4G wireless connectivity. While we acknowledge the potential of VZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

T-Mobile (TMUS) Stock Upgraded Despite Concerns Over Fiber Strategy and Market Slowdown
T-Mobile (TMUS) Stock Upgraded Despite Concerns Over Fiber Strategy and Market Slowdown

Yahoo

time34 minutes ago

  • Yahoo

T-Mobile (TMUS) Stock Upgraded Despite Concerns Over Fiber Strategy and Market Slowdown

T-Mobile US, Inc. (NASDAQ:TMUS) ranks among the . Redburn-Atlantic upgraded its rating of T-Mobile US, Inc. (NASDAQ:TMUS) from Sell to Neutral on July 7 with a price target of $228. The upgrade came despite Redburn-Atlantic's worries that T-Mobile may be vulnerable to a prolonged slowdown in market net additions. According to the firm, T-Mobile US, Inc. (NASDAQ:TMUS) may be the most susceptible to any coordinated market shift toward convergence since it has the least developed fiber strategy of the three major wireless companies. Despite these reservations, the firm recognized T-Mobile's track record of fulfilling mid-term financial projections and noted that, on the majority of multiples, T-Mobile US, Inc. (NASDAQ:TMUS) will be on par with or cheaper than AT&T by 2027 while expanding faster. Based in Bellevue, Washington, T-Mobile US, Inc. (NASDAQ:TMUS) is a well-known supplier of wireless telecommunication services. Renowned for its strides in the 5G space, the company has built one of the largest and fastest 5G networks in the US, setting itself up for long-term success. While we acknowledge the potential of TMUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers
ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

Yahoo

time2 hours ago

  • Yahoo

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell's deep expertise and track record. LONDON & NEW YORK, July 29, 2025--(BUSINESS WIRE)--ViroCell Biologics ("ViroCell"), a specialist viral vector Contract Development and Manufacturing Organisation ("CDMO") for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases. AvenCell's AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an "off-the-shelf" product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer ("NK") cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell's RevCAR™ receptor in AVC203 allows for additional antigen targeting (with "off/on" capability in vivo) beyond CD19 and CD20. AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO's expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell's accelerated timeline. This program evidences ViroCell's ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell's timelines for clinical entry. AvenCell's AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025. John W. Hadden II, CEO of ViroCell, commented: "We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell's accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform." Andrew Schiermeier, Ph.D., CEO, AvenCell, added: "We are delighted with ViroCell's performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can't. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed." Notes to editor: ViroCell ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization ("CDMO") focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. AvenCell Therapeutics AvenCell derives its name from the French word "avenir" to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches. AvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany. View source version on Contacts For more information, please contact: ViroCell John W. Hadden II, CEOinfo@ For media enquiries, please contact: ViroCell – FTI Consulting Simon Conway / Tim StamperViroCell@ +44 (0)20 3727 1000 AvenCell – H Advisors Emma +1 (917) 763-6685 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store